MALDI-TOF/MS Analysis of Extracellular Vesicles Released by Cancer Cells
Abstract
:1. Introduction
2. Applications
2.1. Mesothelioma
2.2. Breast Cancer
2.3. Colorectal Cancer
2.4. Melanoma
2.5. Lung Cancer
2.6. Genitourinary Cancers
2.7. Brain Tumors
2.8. Osteosarcoma
2.9. Liver Cancer
3. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Raposo, G.; Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, and friends. J. Cell Biol. 2013, 200, 373–383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jabeen, S.; Thirumalai, V. The interplay between electrical and chemical synaptogenesis. J. Neurophysiol. 2018, 120, 1914–1922. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dang, V.D.; Jella, K.K.; Ragheb, R.R.T.; Denslow, N.D.; Alli, A.A. Lipidomic and proteomic analysis of exosomes from mouse cortical collecting duct cells. FASEB J. 2017, 31, 5399–5408. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ridder, K.; Keller, S.; Dams, M.; Rupp, A.K.; Schlaudraff, J.; Del Turco, D.; Starmann, J.; Macas, J.; Karpova, D.; Devraj, K.; et al. Extracellular Vesicle-Mediated Transfer of Genetic Information between the Hematopoietic System and the Brain in Response to Inflammation. PLoS Biol. 2014, 12, e1001874. [Google Scholar] [CrossRef] [PubMed]
- Doyle, L.M.; Wang, M.Z. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells 2019, 8, 727. [Google Scholar] [CrossRef] [Green Version]
- EL Andaloussi, S.; Mager, I.; Breakefield, X.; Wood, M. Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 2013, 12, 347–357. [Google Scholar] [CrossRef]
- Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell Vesic. 2018, 7, 1535750. [Google Scholar] [CrossRef] [Green Version]
- Ilango, S.; Paital, B.; Jayachandran, P.; Padma, P.R.; Nirmaladevi, R. Epigenetic alterations in cancer. Front. Biosci.–Landmark 2020, 25, 1058–1109. [Google Scholar]
- Milane, L.; Singh, A.; Mattheolabakis, G.; Suresh, M.; Amiji, M.M. Exosome mediated communication within the tumor microenvironment. J. Control. Release 2015, 219, 278–294. [Google Scholar] [CrossRef]
- Han, L.; Lam, E.W.F.; Sun, Y. Extracellular vesicles in the tumor microenvironment: Old stories, but new tales. Mol. Cancer 2019, 18, 1–14. [Google Scholar] [CrossRef] [Green Version]
- Xu, R.; Rai, A.; Chen, M.; Suwakulsiri, W.; Greening, D.W.; Simpson, R.J. Extracellular vesicles in cancer—implications for future improvements in cancer care. Nat. Rev. Clin. Oncol. 2018, 15, 617–638. [Google Scholar] [CrossRef] [PubMed]
- Thakur, A.; Parra, D.C.; Motallebnejad, P.; Brocchi, M.; Chen, H.J. Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact. Mater. 2022, 10, 281–294. [Google Scholar] [CrossRef] [PubMed]
- Yokoi, A.; Ochiya, T. Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology. Semin. Cancer Biol. 2021, 74, 79–91. [Google Scholar] [CrossRef] [PubMed]
- Szwedowicz, U.; Lapinska, Z.; Gajewska-Naryniecka, A.; Choromanska, A. Exosomes and Other Extracellular Vesicles with High Therapeutic Potential: Their Applications in Oncology, Neurology, and Dermatology. Molecules 2022, 27, 1303. [Google Scholar] [CrossRef] [PubMed]
- Li, P.; Kaslan, M.; Lee, S.H.; Yao, J.; Gao, Z. Progress in Exosome Isolation Techniques. Theranostics 2017, 7, 789–804. [Google Scholar] [CrossRef]
- Cho, Y.T.; Su, H.; Huang, T.L.; Chen, H.C.; Wu, P.W.J.; Wu, C.; Wu, D.C.; Shiea, J. Matrix-assisted laser desorption ionization/time-of-flight mass spectrometry for clinical diagnosis. Clin. Chim. Acta 2013, 415, 266–275. [Google Scholar] [CrossRef]
- Zambonin, C.; Aresta, A. MALDI-TOF/MS Analysis of Non-Invasive Human Urine and Saliva Samples for the Identification of New Cancer Biomarkers. Molecules 2022, 27, 1925. [Google Scholar] [CrossRef]
- Jalaludin, I.; Lubman, D.M.; Kim, J. MALDI-MS: A Powerful but Underutilized Mass Spectrometric Technique for Exosome Research. Mass Spectrom. Lett. 2021, 12, 93–105. [Google Scholar]
- Lagniau, S.; Lamote, K.; van Meerbeeck, J.P.; Vermaelen, K.Y. Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? Oncotarget 2017, 32, 53751–53762. [Google Scholar] [CrossRef] [Green Version]
- Hegmans, J.P.J.J.; Bard, M.P.L.; Hemmes, A.; Luider, T.M.; Kleijmeer, M.J.; Prins, J.B.; Zitvogel, L.; Burgers, S.A.; Hoogsteden, H.C.; Lambrecht, B.N. Proteomic Analysis of Exosomes Secreted by Human Mesothelioma Cells. Am. J. Pathol. 2004, 164, 1807–1815. [Google Scholar] [CrossRef] [Green Version]
- Hegmans, J.P.J.J.; Gerber, P.J.; Lambrecht, B.N. Exosomes. Methods Mol. Biol. 2008, 484, 97–109. [Google Scholar] [PubMed]
- Wu, H.-J.; Chu, P.-Y. Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. Int. J. Mol. Sci. 2021, 22, 636. [Google Scholar] [CrossRef] [PubMed]
- Palazzolo, G.; Albanese, N.N.; Di Cara, G.; Gygax, D.; Vittorelli, M.L.; Pucci-Minafra, I. Proteomic Analysis of Exosome-like Vesicles Derived from Breast Cancer Cells. Anticancer Res. 2012, 32, 847–860. [Google Scholar] [PubMed]
- Klinke, D.J., II; Kulkarni, Y.M.; Wu, Y.; Byrne-Hoffman, C. Inferring Alterations in Cell-to-Cell Communication in HER2þ Breast Cancer Using Secretome Profiling of Three Cell Models. Biotechnol. Bioeng. 2014, 111, 1853–1863. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tamkovich, S.N.; Somov, A.K.; Karpukhina, K.V.; Grigoreva, A.E.; Yunusova, N.V.; Stakheeva, M.N.; Voytsitskiy, V.E.; Kondakova, I.V.; Laktionov, P.P. Isolation and characterization of exosomes from blood of patients with mastopathy and breast cancer. AIP Conf. Proc. 2017, 1882, 020075. [Google Scholar]
- Tutanov, O.S.; Bakakina, Y.S.; Proskura, K.V.; Grigoryeva, A.E.; Syakhovich, V.E.; Beliaev, S.A.; Ryabchikova, E.I.; Tsentalovich, Y.P.; Laktionov, P.P.; Tamkovich1, S.N. Search for Breast Cancer Proteomic Markers in Total Blood Exosomes. Sib. J. Oncol. 2020, 19, 49–61. [Google Scholar] [CrossRef]
- Tutanov, O.S.; Proskura, K.V.; Grigoryeva, A.E.; Tsentalovich, Y.P.; Tamkovich, S.N. Identification of Tumor Dissemination Facilitating Proteins in Exosomes Associated with Blood Cells of Breast Cancer Patients. Russ. J. Bioorg. Chem. 2020, 46, 1018–1033. [Google Scholar] [CrossRef]
- Zheng, H.; Zhao, J.; Wang, X.; Yan, S.; Chu, H.; Gao, M.; Zhang, X. Integrated Pipeline of Rapid Isolation and Analysis of Human Plasma Exosomes for Cancer Discrimination Based on Deep Learning of MALDI-TOF MS Fingerprints. Anal. Chem. 2022, 94, 1831–1839. [Google Scholar] [CrossRef]
- Tieng, F.Y.F.; Abu, N.; Nasir, S.N.; Lee, L.-H.; Ab Mutalib, N.-S. Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells. Diagnostics 2021, 11, 2136. [Google Scholar] [CrossRef]
- Klein-Scory, S.; Kübler, S.; Diehl, H.; Eilert-Micus, C.; Reinacher-Schick, A.; Stühler, K.; Warscheid, B.; Meyer, H.E.; Schmiegel, W.; Schwarte-Waldhoff, I. Immunoscreening of the extracellular proteome of colorectal cancer cells. BMC Cancer 2010, 10, 70. [Google Scholar] [CrossRef] [Green Version]
- Stubiger, G.; Nairn, M.D.; Abban, T.K.; Openshaw, M.E.; Mancera, L.; Herzig, B.; Wuczkowski, M.; Senfter, D.; Mader, R.M. MALDI-MS Protein Profiling of Chemoresistance in Extracellular Vesicles of Cancer Cells. Anal. Chem. 2018, 90, 13178–13182. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teixido, C.; Castillo, P.; Martinez-Vila, C.; Arance, A.; Alos, L. Molecular Markers and Targets in Melanoma. Cells 2021, 10, 2320. [Google Scholar] [CrossRef] [PubMed]
- Schiera, G.; Di Liegro, C.M.; Puleo, V.; Colletta, O.; Fricano, A.; Cancemi, P.; Di Cara, G.; Di Liegro, I. Extracellular vesicles shed by melanoma cells contain a modified form of H1.0 linker histone and H1.0 mRNA-binding proteins. Internat. J. Oncol. 2016, 49, 1807–1814. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, Y.; Pick, H.; Gasilova, N.; Li, X.; Lin, T.E.; Laeubli, H.P.; Zippelius, A.; Ho, P.C.; Girault, H.H. MALDI Detection of Exosomes: A Potential Tool for Cancer Studies. Chem 2019, 5, 1318–1336. [Google Scholar] [CrossRef]
- Lobasso, S.; Tanzarella, P.; Mannavola, F.; Tucci, M.; Silvestris, F.; Felici, C.; Ingrosso, C.; Corcelli, A.; Lopalco, P. A Lipidomic Approach to Identify Potential Biomarkers in Exosomes From Melanoma Cells with Different Metastatic Potential. Front. Physiol. 2021, 12, 748895. [Google Scholar] [CrossRef]
- Dai, W.; Feng, J.; Hu, X.; Chen, Y.; Gu, Q.; Gong, W.; Feng, T.; Wu, J. SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer. Cancer Cell Int. 2021, 21, N106. [Google Scholar] [CrossRef]
- Jia, Z.; Patra, A.; Kutty, V.K.; Venkatesan, T. Critical Review of Volatile Organic Compound Analysis in Breath and In Vitro Cell Culture for Detection of Lung Cancer. Metabolites 2019, 9, 52. [Google Scholar] [CrossRef] [Green Version]
- Jung, J.H.; Lee, M.Y.; Choi, D.Y.; Lee, J.W.; You, S.; Lee, K.Y.; Kim, J.; Kim, K.P. Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells. Proteomics 2015, 15, 824–835. [Google Scholar] [CrossRef] [Green Version]
- Choi, E.S.; Faruque, H.A.; Kim, J.H.; Kim, K.J.; Choi, J.E.; Kim, B.A.; Kim, B.; Kim, Y.J.; Woo, M.H.; Park, J.Y.; et al. CD5L as an Extracellular Vesicle-Derived Biomarker for Liquid Biopsy of Lung Cancer. Diagnostics 2021, 11, 620. [Google Scholar] [CrossRef]
- Aresta, A.; Calvano, C.D.; Palmisano, F.; Zambonin, C.; Monaco, A.; Tommasi, S.; Pilato, B.; Paradiso, A. Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry. J. Pharm. Biomed. Anal. 2008, 46, 157–164. [Google Scholar] [CrossRef]
- Calvano, C.D.; Aresta, A.; Iacovone, M.; De Benedetto, G.E.; Zambonin, C.; Battaglia, M.; Ditonno, P.; Rutigliano, M.; Bettocchi, C. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles. J. Pharm. Biomed. Anal. 2010, 51, 907–914. [Google Scholar] [CrossRef] [PubMed]
- Yu, Z.; Zhao, C.; Hu, S.; Zhang, H.; Li, W.; Zhang, R.; Luo, Q.; Yang, H. MALDI-MS-based biomarker analysis of extracellular vesicles from human lung carcinoma cells. RSC Adv. 2021, 11, 25375. [Google Scholar] [CrossRef] [PubMed]
- Harvey, P.; Basuita, A.; Endersby, D.; Curtis, B.; Iacovidou, A.; Walker, M. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol. 2009, 9, 14–22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alberice, J.V.; Amaral, A.F.; Armitage, E.G.; Lorente, J.A.; Algaba, F.; Carrilho, E.; Marquez, M.; Garcia, A.; Malats, N.; Barbas, C. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach. J. Chromatogr. A 2013, 13, 163–170. [Google Scholar] [CrossRef]
- Goran Ronquist, K.; Ronquist, G.; Larsson, A.; Carlsson, L. Proteomic Analysis of Prostate Cancer Metastasis-derived Prostasomes. Anticancer Res. 2010, 30, 285–290. [Google Scholar]
- Nyalwidhe, J.O.; Betesh, L.R.; Powers, T.W.; Jones, E.E.; White, K.Y.; Burch, T.C.; Brooks, J.; Watson, M.T.; Lance, R.S.; Troyer, D.A.; et al. Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression. Proteom. Clin. Appl. 2013, 7, 677–689. [Google Scholar] [CrossRef] [Green Version]
- Welton, J.L.; Khanna, S.; Giles, P.J.; Brennan, P.; Brewis, I.A.; Staffurth, J.; Mason, M.D.; Clayton, A. Proteomics Analysis of Bladder Cancer Exosomes. Mol. Cell. Proteom. 2010, 9, 1324–1338. [Google Scholar] [CrossRef] [Green Version]
- Lin, S.Y.; Chang, C.H.; Wu, H.C.; Lin, C.C.; Chang, K.P.; Yang, C.R.; Huang, C.P.; Hsu, W.H.; Chang, C.T.; Chen, C.J. Proteome Profiling of Urinary Exosomes Identifies Alpha 1-Antitrypsin and H2B1K as Diagnostic and Prognostic Biomarkers for Urothelial Carcinoma. Sci. Rep. 2016, 6, 34446. [Google Scholar] [CrossRef]
- Zou, G.; Benktander, J.D.; Gizaw, S.T.; Gaunitz, S.; Novotny, M.V. Comprehensive Analytical Approach toward Glycomic Characterization and Profiling in Urinary Exosomes. Anal. Chem. 2017, 89, 5364–5372. [Google Scholar] [CrossRef]
- Sourani, A.; Saghaei, S.; Sabouri, M. A systematic review of extracellular vesicles as non-invasive biomarkers in glioma diagnosis, prognosis, and treatment response monitoring. Mol. Biol. Rep. 2021, 48, 6971–6985. [Google Scholar] [CrossRef]
- Costa, J.; Gatermann, M.; Nimtz, M.; Kandzia, S.; Glatzel, M.; Conradt, H.S. N-Glycosylation of Extracellular Vesicles from HEK-293 and Glioma Cell Lines. Anal. Chem. 2018, 90, 7871–7879. [Google Scholar] [CrossRef]
- Di Giuseppe, F.; Carluccio, M.; Zuccarini, M.; Giuliani, P.; Ricci-Vitiani, L.; Pallini, R.; De Sanctis, P.; Di Pietro, R.; Ciccarelli, R.; Angelucci, S. Proteomic Characterization of Two Extracellular Vesicle Subtypes Isolated from Human Glioblastoma Stem Cell Secretome by Sequential Centrifugal Ultrafiltration. Biomedicines 2021, 9, 146. [Google Scholar] [CrossRef] [PubMed]
- Shtam, T.A.; Naiyzhny, S.N.; Landa, S.B.; Burdackov, V.S.; Artamonova, T.O.; Filatov, M.V. Isolation and proteomic analysis of exosomes secreted by human cancer cells in vitro. Tsitologiya 2012, 54, 430–438. [Google Scholar]
- Behjati, S.; Tarpey, P.S.; Haase, K.; Ye, H.; Young, M.D.; Alexandrov, L.B.; Farndon, S.J.; Collord, G.; Wedge, D.C.; Martincorena, I.; et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat. Commun. 2017, 8, 15936. [Google Scholar] [CrossRef] [PubMed]
- Han, Z.; Yi, J.; Yang, Y.; Li, D.; Peng, C.; Long, S.; Peng, X.; Shen, Y.; Liu, B.; Qiao, L. SERS and MALDI-TOF MS based plasma exosome profiling for rapid detection of osteosarcoma. Analyst 2021, 146, 6496–6505. [Google Scholar] [CrossRef]
- Han, Z.; Peng, C.; Yi, J.; Wang, Y.; Liu, Q.; Yang, Y.; Long, S.; Qiao, L.; Shen, Y. Matrix-assisted laser desorption ionization mass spectrometry profiling of plasma exosomes evaluates osteosarcoma metastasis. iScience 2021, 24, 102906. [Google Scholar] [CrossRef]
- Li, S.; Chen, L. Exosomes in Pathogenesis, Diagnosis, and Treatment of Hepatocellular Carcinoma. Front. Oncol. 2022, 12, 793432. [Google Scholar] [CrossRef]
- Tan, E.J.; Thuault, S.; Caja, L.; Carletti, T.; Heldin, C.H.; Moustakas, A. Regulation of Transcription Factor Twist Expression by the DNA Architectural Protein High Mobility Group A2 during Epithelial-to-Mesenchymal Transition. Cell Biol. 2012, 287, 7134–7145. [Google Scholar] [CrossRef] [Green Version]
- Karaosmanoglu, O.; Banerjee, S.; Sivas, H. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells. Cell. Oncol. 2018, 41, 439–453. [Google Scholar] [CrossRef]
Authors | Cancer Type | Objective | Main Findings | Ref |
---|---|---|---|---|
Hegmans et al. | Mesothelioma | Proteomic analysis of exosomes | Identification of several proteins | [20] |
Palazzolo et al. | Breast | Proteomic analysis of exosome-like vesicles | 179 proteins identified, 32 isoforms upregulated in the vesicles in comparison to whole cell lysates | [23] |
Klinke et al. | Breast | Proteomic analysis of secretome to detect alterations in cell-to-cell communication | Different secretome profiles observed between cancer and normal cells | [24] |
Tamkovich et al. | Breast | Proteomic characterization of blood exosomes | Detection of several proteins with different expression between healthy and cancer patients | [25] |
Tutanov et al. | Breast | Search for protein biomarkers in total blood exosomes | Proteins associated with breast cancer detected only in total blood exosomes of cancer patients | [26] |
Tutanov et al. | Breast and pancreatic | Investigation on the role of blood exosomes in tumor dissemination | 64% of the proteins of tumor origin identified in cancer patients | [27] |
Zheng et al. | Breast | Isolation and fingerprinting of plasma exosomes | Differentiation of different cancer types through a multi-classifier artificial neural network model using MS peaks as inputs | [28] |
Klein-Scory et al. | Colorectal | Immunoscreening of the secretome for the identification of tumor biomarkers | Two potential protein markers proposed, Glod4 and a C-terminal fragment of agrin | [30] |
Stubiger et al. | Colorectal | Protein profiling of EVs to monitor chemoresistance | Discriminatory protein patterns as the result of increased chemoresistance of parent cells | [31] |
Schiera et al. | Melanoma | Investigation on the presence in EVs of H1.0 linker histone variant | Evidence of the presence of modified H1.0 histone, the corresponding mRNA, and the transcription factor MYEF2 | [33] |
Zhu et al. | Melanoma | Protein fingerprinting of bloodstream-circulating whole exosomes | Classification of different lines from tumor stage level through mathematical analysis. Detection of biomarkers | [34] |
Lobasso et al. | Melanoma | Lipid profiling of intact cells and related exosomes | Information on the lipid content of melanoma. Bis(monoacylglycero)phosphate proposed as a specific lipid marker of exosomes | [35] |
Jung et al. | Lung | Phospholipid profiling of EVs searching for markers for gefitinib resistance prediction | Changes in EVs phospholipidomic profiles directly related to gefitinib resistance | [38] |
Choi et al. | Lung | Search for new tumor markers in EVs from serum and secreted by cell lines | 7 proteins expressed at high levels in tumor EVs. CD5L suggested as biomarker for the disease in serum EVs | [39] |
Yu et al. | Lung | Optimization of experimental protocols for EVs protein profiling | Medium components and ultracentrifugation procedures indicated as key factors. Detection of S100A10 and RPS27A proteins | [42] |
Goran Ronquist et al. | Prostate | Proteomic characterization of metastasis-derived prostasomes | Identification of angiogenic factors dimethylarginine dimethylaminohydrolase 1 and annexins A1, A3, A5 | [45] |
Nyalwidhe et al. | Prostate | N-linked glycan profiling of expressed prostatic secretions and exosomes | Changes in glycosylation appeared to reflect the clinical status of prostate cancer | [46] |
Welton et al. | Bladder | Proteomic analysis of exosomes | 353 exosomic proteins (72 for the first time) identified. Strong correlations between the observed proteome and cancer | [47] |
Lin et al. | Urothelial | Proteomic profiling of urinary exosomes | Identification of alpha-1-antitrypsin and histone H2B1K as diagnostic and prognostic markers | [48] |
Costa et al. | Glioma | Characterization of N-glycans from EVs glycoproteins and comparison with total cellular membranes | Different profiles observed in EVs and in cellular membranes | [51] |
Di Giuseppe et al. | Glioblastoma | Proteomic characterization of two subtypes of EVs shed by cancer stem-like cells | Identification of specific proteins with different functions for each subpopulation | [52] |
Shtam et al. | Brain | Development of methods for exosomes analysis | Description of the protein composition of exosomes | [53] |
Han et al. | Osteosarcoma | Plasma exosome profiling for rapid detection of cancer | Discrimination between cancer patients and healthy subjects | [55] |
Han et al. | Osteosarcoma | Profiling of plasma exosomes to evaluate metastasis | Differentiation between patients with metastasis, patients without metastasis, and healthy individuals. 7 proteins proposed as possible metastasis biomarkers | [56] |
Karaosmanoglu et al. | Hepatocellular | Search for biomarkers for partial epithelial-to-mesenchymal transition | Identification of fibronectin 1, collagen type II alpha 1 and fibrinogen gamma chain as markers for chemo-resistance and partial epithelial-to-mesenchymal transition | [59] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zambonin, C. MALDI-TOF/MS Analysis of Extracellular Vesicles Released by Cancer Cells. Appl. Sci. 2022, 12, 6149. https://doi.org/10.3390/app12126149
Zambonin C. MALDI-TOF/MS Analysis of Extracellular Vesicles Released by Cancer Cells. Applied Sciences. 2022; 12(12):6149. https://doi.org/10.3390/app12126149
Chicago/Turabian StyleZambonin, Carlo. 2022. "MALDI-TOF/MS Analysis of Extracellular Vesicles Released by Cancer Cells" Applied Sciences 12, no. 12: 6149. https://doi.org/10.3390/app12126149